Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 3 CLINICAL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BNT162B2 RNA-BASED, VARIANT-ADAPTED VACCINE CANDIDATE(S) AGAINST SARS-COV-2 IN CHILDREN AND ADULTS

NCT07798648 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT07798648
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07798648 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 3 CLINICAL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BNT162B2 RNA-BASED, VARIANT-ADAPTED VACCINE CANDIDATE(S) AGAINST SARS-COV-2 IN CHILDREN AND ADULTS
Lead sponsor
BioNTech SE
Phase
Phase 3
Overall status
Recruiting
Start date
August 31, 2026
Completion date
April 21, 2027
Enrollment
700 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 vaccines